Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGC-M3
- Development stage
- Preclinical
- Lead developer
- IGC Pharma
- Modality
- Small Molecules
01
Overview
IGC-M3 is a small molecule drug candidate in preclinical development by IGC Pharma. It is designed to inhibit the aggregation of amyloid-beta (Aβ) plaques, which are implicated in the pathogenesis of Alzheimer's disease. By targeting Aβ plaque aggregation, IGC-M3 aims to impact early-stage Alzheimer's disease and potentially slow or prevent disease progression. The drug represents part of a broader portfolio from IGC Pharma focused on innovative approaches for Alzheimer’s therapy[1][2][4][5].
- Other names
- M3-IGC Pharma-AI pharma aggregatorM-3-IGC Pharma-AI pharma aggregatorM 3-IGC Pharma-AI pharma aggregator
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on IGC-M3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGC-M3.